keyboard_arrow_up

Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

The Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future road map, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

Key Findings:

  • Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
  • As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
  • In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
  • In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered:

  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry road map and value chain
  • Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Inquire for Discount at http://www.reportsnreports.com/contacts/discount.aspx?name=344436.

Historical Revenue & Forecast Segmentation:

Market forecasts are provided for each of the following sub markets and their subcategories:

  • Brand Classification
  • Pure (Non-branded) Generics
  • Branded Generics
  • Super Generics

Therapeutic Area

  • Antibiotics
  • Cardiovascular & Hypertension
  • CNS (Central Nervous System)
  • Dermatology
  • Diabetes
  • Gastrointestinal
  • Hormonal Drugs
  • Oncology
  • Pain Relief
  • Respiratory
  • Rheumatology
  • Others

Regional Markets

  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America

Country Markets

  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA

Key Questions Answered:

The report provides answers to the following key questions:

  • How big is the generic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and sub markets will see the highest percentage of growth?
  • How big is the market for generic cancer drugs?
  • How does regulation impact the adoption of generic drugs?
  • How will branded and super generics impact revenue prospects?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of biologics impact the market?
  • What are the future prospects of approved and non-approved biosimilar drugs?
  • What strategies should generic and innovator drug manufacturers adopt to remain competitive?

Buy a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=344436.

List of Companies Mentioned

  • Abbott Laboratories
  • AbbVie
  • ACETO Corporation
  • Acino Holding
  • Actavis
  • Actelion
  • Adcock Ingram
  • Aesica Pharmaceuticals
  • Ajinomoto
  • Akron
  • Alexion Pharmaceuticals
  • Alfa Wasserman
  • Allergan
  • Almirall
  • AMA (African Medicines Regulatory Agency)
  • Amgen
  • Amneal Pharmaceuticals
  • AMRI (Albany Molecular Research, Inc.)
  • ApoPharma
  • Apotex
  • Arch Pharmalabs
  • ASKA Pharmaceutical Company
  • Aspen Holdings
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Auxilium Pharmaceuticals
  • Baxter BioScience
  • Baxter International
  • Bayer AG
  • BD (Becton, Dickinson and Company)
  • BD Rx
  • Berlin Chemie
  • Biocon
  • Biogaran
  • Biogen Idec
  • Biogen Laboratorios
  • BMS (Bristol-Myers Squibb)
  • Boehringer Ingelheim
  • Boots UK
  • BPI (Breckenridge Pharmaceutical Inc.)
  • Breckenridge Pharmaceutical
  • Cadila Healthcare (Zydus Cadila)
  • Cadila Pharmaceuticals
  • CBER (Centre for Biologics Evaluation and Research)
  • CDER (Centre for Drug Evaluation and Research)
  • CDSCO (Central Drug Standards and Control Organization, India)
  • Cedarburg Pharmaceuticals
  • Celgene Corporation
  • Celltrion Group
  • CFDA (China Food and Drug Administration)
  • Chiesi Farmaceutici
  • Chugai Pharmaceutical Company
  • Cipla
  • Claris Injectables
  • Claris Lifesciences
  • Claris Otsuka
  • Coherus BioSciences
  • Consort Medical
  • Covidien
  • Cubist Pharmaceuticals
  • Cypress Pharmaceutical
  • Daiichi Sankyo
  • Daiichi Sankyo Espha
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Dusa Pharmaceuticals
  • EGA (European Generic Medicines Association)
  • Egis Pharmaceuticals
  • Eisai Company
  • Eli Lilly and Company
  • Elmed Eisai Company
  • EMA (European Medicines Agency)
  • Endo International
  • Endo Pharmaceuticals
  • ESTEVE Farma
  • ESTEVE Group
  • Eurofarma Laboratorios
  • FDA (Food and Drug Administration)
  • Ferring Pharmaceuticals
  • Forest Laboratories
  • Fresenius Kabi
  • Fuji Pharma Company
  • Fujifilm Corporation
  • Fujifilm Holdings Corporation
  • Fujifilm Pharma Company
  • Galderma
  • Galenika
  • Gedeon Richter
  • Gedeon Richter PregLem
  • Genepharm
  • GGL (Glenmark Generics Limited)
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Global Pharmaceuticals
  • Globalpharma
  • Grifols
  • Gruenenthal Group
  • GSK (GlaxoSmithKline)
  • Guangdong BeiKang Pharmaceutical Company
  • Hanmi Pharmaceutical Company
  • Health Canada
  • Hetero Drugs
  • Hikma Pharmaceuticals
  • Hi-Tech Pharmacal
  • Hospira
  • Impax Laboratories
  • Impax Pharmaceuticals
  • Ipsen
  • Janssen Pharmaceutica
  • Jazz Pharmaceuticals
  • JHP Group Holdings
  • JHP Pharmaceuticals
  • Johnson & Johnson
  • JT (Japan Tobacco)
  • Kaken Pharmaceutical Company
  • Kaneka Corporation
  • Kowa Company
  • Kowa Health Care America
  • Kowa Pharmaceuticals America
  • Kowa Research Institute
  • Kremers Urban Pharmaceuticals
  • Krka (Krka, d. d.)
  • Kyowa Hakko Kirin Company
  • Kyowa Pharmaceutical Industry Company
  • Laboratorios Roemmers
  • Leo Pharma
  • Les Laboratoires Servier
  • Lil Therapeutics
  • Lundbeck (H. Lundbeck A/S)
  • Lupin
  • Mallinckrodt
  • Maruho Company
  • Matrix Laboratories
  • Meda
  • Medley Farma
  • Meiji Holdings
  • Meiji Seika Pharma Company
  • Menarini Group
  • Merck and Co.
  • Merck KGaA
  • Merck Serono
  • Merz Pharma
  • Ministry of Health, Labour and Welfare (Japan)
  • Mitsubishi Chemical Holdings Corporation
  • Mitsubishi Tanabe Pharma
  • Mitsui & Company
  • Mitsui Group
  • MN (Mustafa Nevzat) Pharma
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Company
  • Nippon Kayaku
  • Nippon Shinyaku
  • Nipro Pharma Corporation
  • Novartis International
  • Novo Nordisk
  • OLIC (Thailand)
  • Ono Pharmaceutical Company
  • Orion Corporation
  • Osaka Synthetic Chemical Laboratories
  • Otsuka Holdings Company
  • Otsuka Pharmaceutical Company
  • Paladin Labs
  • Par Pharmaceutical Companies
  • Pensa Dose
  • Pensa Pharm
  • Perrigo Company
  • Pfizer
  • Pharma Dynamics
  • Pharmstandard
  • Pierre Fabre (Laboratoires Pierre Fabre)
  • Piramal Enterprises
  • Piramal Group
  • Pliva (Pliva d.d.)
  • Prasco Laboratories
  • PregLem
  • Purdue Pharma
  • Qualitest and Vintage Pharmaceuticals
  • Ranbaxy Laboratories
  • Recordati
  • Regeneron Pharmaceuticals
  • Rising Pharmaceuticals
  • Roche Holding (F. Hoffmann-La Roche)
  • Roxane Laboratories
  • Salix Pharmaceuticals
  • Samsung Bioepis
  • Samsung BioLogics
  • Samsung Group
  • Sandoz International
  • Sanofi
  • Sanofi-Aventis Nichi-Iko K.K.
  • Santen Pharmaceutical Company
  • Sawai Pharmaceutical Company
  • Seikagaku Corporation
  • Sequent Scientific
  • Servier Group
  • Shionogi & Company
  • Shire
  • Sigma-Tau
  • Somar (Grupo Farmaceutico Somar)
  • STADA Arzneimittel
  • Strativa Pharmaceuticals
  • Strides Arcolab
  • Sumitomo Dainippon Pharma Company
  • Sun Pharmaceutical Industries
  • Supera Farma Laboratorios
  • Taisho Pharmaceutical Company
  • Taisho Pharmaceutical Holdings Company
  • Taisho Pharmaceutical Industries
  • Taiyo Pharmaceutical Industry Company
  • Takeda Pharmaceutical Company
  • Tanabe Seiyaku Hanbai Company
  • Taro Pharmaceutical Industries
  • Teijin
  • Teijin Pharma
  • Teva Pharmaceutical Industries
  • Teva-Kowa Pharma Company
  • The Medicines Company
  • Torrent Group
  • Torrent Pharmaceuticals
  • Towa Pharmaceutical Company
  • UCB
  • United Therapeutics Corporation
  • Valeant Pharmaceuticals International
  • Ventana Medical Systems
  • Vertex Pharmaceuticals
  • Warner-Chilcott
  • West-Ward Pharmaceuticals
  • WHO (World Health Organization)
  • Wockhardt
  • Zentiva